The Liver Meeting 2022

Washington DC, US 04 November 2022 - 08 November 2022

Bepirovirsen shows promise in controlling chronic HBV infection

19 Dec 2022 bởi

Weekly bepirovirsen treatment may help reduce HBsAg* and hepatitis B virus (HBV) DNA levels in patients with chronic HBV infection, the phase IIb B-Clear study showed.

Bepirovirsen shows promise in controlling chronic HBV infection

19 Dec 2022

ALXN1840 generates rapid, sustained copper mobilization in Wilson disease

15 Dec 2022 bởi

In individuals with Wilson disease (WD), a rare disease of copper metabolism, ALXN1840 led to significantly greater copper mobilization compared with standard of care (SoC), findings from a rater-blinded phase III study have shown.

ALXN1840 generates rapid, sustained copper mobilization in Wilson disease

15 Dec 2022

Maralixibat improves pruritus across all PFIC types

14 Dec 2022 bởi

Treatment with maralixibat significantly reduced the severity of pruritus in children with progressive familial intrahepatic cholestasis (PFIC) in the MARCH-PFIC* study presented at The Liver Meeting 2022.

Maralixibat improves pruritus across all PFIC types

14 Dec 2022

Odevixibat improves pruritus, reduces bile acids in children with ALGS

13 Dec 2022 bởi

Treatment with odevixibat, a potent, selective IBAT* inhibitor, significantly improved pruritus and reduced serum bile acid levels in children with Alagille syndrome (ALGS), according to the ASSERT** trial presented at The Liver Meeting 2022.

Odevixibat improves pruritus, reduces bile acids in children with ALGS

13 Dec 2022

Resmetirom safe, effective in improving NASH fibrosis markers

12 Dec 2022 bởi

Treatment with the selective THR-β* agonist resmetirom for 52 weeks was well-tolerated and effective in reducing markers of NASH** fibrosis in a well-compensated Child-Pugh (CP)-A NASH population, a phase III trial has shown.

Resmetirom safe, effective in improving NASH fibrosis markers

12 Dec 2022

Midodrine a novel option for PICD prevention in ACLF

06 Dec 2022 bởi

Oral midodrine may be a good alternative to intravenous albumin for preventing paracentesis-induced circulatory dysfunction (PICD) in patients with acute-on-chronic liver failure (ACLF) undergoing modest-volume paracentesis for ascites, suggests a new study.

Midodrine a novel option for PICD prevention in ACLF

06 Dec 2022